Protective Effects of Mycelium on the Development of Osteoarthritis After Monosodium Iodoacetate Injection
Overview
Affiliations
Objective: The aim of this study was to identify the protective effects of mycelium (PLM) and its possible mechanisms in a model of monosodium iodoacetate- (MIA-) induced osteoarthritis (OA).
Methods: Intra-articular injection of MIA was injected to 50 L with 80 mg/mL using a 0.3 mL insulin syringe into the right knee joint. Changes in hindpaw weight-bearing distribution between the right (osteoarthritic) and left (contralateral control) legs were used as an index of joint discomfort. PLM (50, 100, and 200 mg/kg body weight) was orally administered once daily for 14 days from day 7 after MIA treatment. And then, various factors associated with inflammatory response and cartilage degeneration in cartilage tissues detected by western blotting.
Results: PLM treatment showed a concentration-dependent elevation in change in hindpaw weight-bearing distribution (HWBD). PLM200 demonstrated the capacity to significantly increase HWBD, indicating that the change in weight-bearing distribution means the reduction of spontaneous pain. Our results indicate that PLM suppressed the inflammatory factors via NF-B signaling pathway induced by p38 phosporlyation. Moreover, PLM200 exhibited a significant reduction of ROS produced by the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase. PLM100 and PLM200 inhibited the levels of matrix metalloproteinase (MMP)-1, one of proteinase that degrades extracellular matrix (ECM).
Conclusions: Taken together, our results indicated that PLM has a strong chondroprotective effect through the suppression both ROS production and inflammation.
Tee P, Krishnan T, Cheong X, Maniam S, Looi C, Ooi Y Fungal Biol Biotechnol. 2024; 11(1):7.
PMID: 38987829 PMC: 11238383. DOI: 10.1186/s40694-024-00176-3.
Chiang Y, Huang K, Wang K, Huang Y, Chen H, Ali M Mar Drugs. 2024; 22(5).
PMID: 38786602 PMC: 11123468. DOI: 10.3390/md22050211.
Shin M, Kim H, Choi H, Park K, Choi H, Roh S Evid Based Complement Alternat Med. 2022; 2022:3067526.
PMID: 36310623 PMC: 9605825. DOI: 10.1155/2022/3067526.
Suh M, Shin H, Jeong E, Kim G, Jeong S, Ha E Pharmaceuticals (Basel). 2022; 15(10).
PMID: 36297326 PMC: 9612016. DOI: 10.3390/ph15101215.
Lee Y, Son E, Kim S, Kim D Nutrients. 2022; 14(7).
PMID: 35405969 PMC: 9003109. DOI: 10.3390/nu14071356.